| Autor: |
Fortner, Renee T. Sarink, Danja Schock, Helena Johnson, Theron Tjonneland, Anne Olsen, Anja Overvad, Kim Affret, Aurelie His, Mathilde Boutron-Ruault, Marie-Christine and Boeing, Heiner Trichopoulou, Antonia Naska, Androniki and Orfanos, Philippos Palli, Domenico Sieri, Sabina Mattiello, Amalia Tumino, Rosario Ricceri, Fulvio Bueno-de-Mesquita, H. Bas Peeters, Petra H. M. Van Gils, Carla H. Weiderpass, Elisabete Lund, Eiliv Quiros, J. Ramon Agudo, Antonio and Sanchez, Maria-Jose Chirlaque, Maria-Dolores Ardanaz, Eva and Dorronsoro, Miren Key, Tim Khaw, Kay-Tee Rinaldi, Sabina and Dossus, Laure Gunter, Marc Merritt, Melissa A. Riboli, Elio and Kaaks, Rudolf |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Popis: |
Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1: 1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER-breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER-breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p(trend) = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER-disease did not differ by menopausal status at blood collection (p(het) = 0.97), and we observed no heterogeneity by HT use at blood collection (p(het) >= 0.43) or age at breast cancer diagnosis (p(het) >= 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER-breast cancer. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
